Last reviewed · How we verify
SP + amodiaquine
Sulfadoxine and pyrimethamine work by inhibiting dihydropteroate synthase and dihydrofolate reductase, respectively, disrupting folic acid synthesis in Plasmodium parasites.
Sulfadoxine and pyrimethamine work by inhibiting dihydropteroate synthase and dihydrofolate reductase, respectively, disrupting folic acid synthesis in Plasmodium parasites. Used for Uncomplicated malaria, Cerebral malaria.
At a glance
| Generic name | SP + amodiaquine |
|---|---|
| Sponsor | London School of Hygiene and Tropical Medicine |
| Drug class | Antimalarial |
| Target | Dihydropteroate synthase, Dihydrofolate reductase |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Sulfadoxine and pyrimethamine are antifolate drugs that target the folate biosynthesis pathway in Plasmodium parasites. By inhibiting dihydropteroate synthase and dihydrofolate reductase, they prevent the parasites from synthesizing folic acid, which is essential for their survival and replication. This leads to the death of the parasites and ultimately, the clearance of the infection.
Approved indications
- Uncomplicated malaria, Cerebral malaria
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Rash
- Headache
Key clinical trials
- Perennial Malaria Chemoprevention in the Malaria Vaccine Era (PHASE4)
- Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi (PHASE4)
- Parasite Clearance and Protection from Infection (PCPI) in Cameroon (PHASE3)
- Efficacy and Safety of Sulphadoxine-pyrimethamine and Amodiaquine in Ghanaian Pregnant Women (PHASE3)
- Evaluation of Vector and Chemoprevention-based Interventions to Reduce Malaria Burden in Urban Daaras of Touba, Senegal (PHASE4)
- Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) Extension Study (PHASE3)
- Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE) (PHASE4)
- Seasonal Malaria Chemoprevention Rapid Assessment Study Mozambique (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SP + amodiaquine CI brief — competitive landscape report
- SP + amodiaquine updates RSS · CI watch RSS
- London School of Hygiene and Tropical Medicine portfolio CI